نتائج البحث - "E. A. Pavlovskaya"

1

دورية أكاديمية

Effect of combination antihypertensive therapy, including renin-angiotensin-aldosterone system inhibitors, on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction

المؤلفون: Z. M. Akhilgova, A. P. Roitman, N. G. Rakova, A. V. Bugrov, E. A. Pavlovskaya, M. S. Zastrozhin, A. G. Avtandilov

المصدر: Российский кардиологический журнал, Vol 26, Iss 5 (2021)

مصطلحات موضوعية: endothelial dysfunction, oxidative stress, heart failure with preserved ejection fraction, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://russjcardiol.elpub.ru/jour/article/view/4158Test; https://doaj.org/toc/1560-4071Test; https://doaj.org/toc/2618-7620Test

الوصول الحر: https://doaj.org/article/16c7908c87254ac49424253d9beada83Test

View record in DOAJ

2

دورية أكاديمية

Medical visualization in pregnancy: indications, limitations and prospects ; Показания, ограничения и возможности применения методов лучевой диагностики у беременных женщин

المؤلفون: E. A. Pavlovskaya, Sergey S. Bagnenko, Ilya A. Burovik, Ekaterina A. Busko, Stanislav A. Tiatkov, Pavel Yu. Grishko, Igor V. Berlev, Е. А. Павловская, С. С. Багненко, И. А. Буровик, Е. А. Бусько, С. А. Тятьков, П. Ю. Гришко, И. В. Берлев

المصدر: Medical Visualization; Принято в печать ; Медицинская визуализация; Принято в печать ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: тератогенное воздействие, pregnancy, safety, US, MRI, computer tomography, ionization, scintigraphy, PET, teratogenic effect, беременные, безопасность, УЗИ, МРТ, КТ, ионизирующее излучение, сцинтиграфия, ПЭТ

وصف الملف: application/pdf

العلاقة: https://medvis.vidar.ru/jour/article/view/1408/876Test; https://medvis.vidar.ru/jour/article/downloadSuppFile/1408/2223Test; https://medvis.vidar.ru/jour/article/downloadSuppFile/1408/2224Test; https://medvis.vidar.ru/jour/article/downloadSuppFile/1408/2229Test; Трофимова Т.Н., Халиков А.Д., Семенова М.Д. Возможности магнитно-резонансной томографии в изучении формирования головного мозга плода. Лучевая диагностика и терапия. 2017; 4 (8): 6–16. https://doi.org/10.22328/2079-5343-2017-4-6-15Test; Amant F., Berveiller P., Boere I.A. et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann. Oncol. 2019; 30 (10): 1601–1612. https://doi.org/10.1093/annonc/mdz228Test; Parpinel G., Laudani M.E., Giunta F.P. et al. Use of positron emission tomography for pregnancy-associated cancer assessment: a review. J. Clin. Med. 2022; 11 (13): 1–11. https://doi.org/10.3390/jcm11133820Test; de Haan J., Verheecke M., Van Calsteren K. et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018; 19 (3): 337–346. https://doi.org/10.1016/S1470-2045Test(18)30059-7; Abramowicz J.S., Kremkau F.W., Merz E. Obstetrical ultrasound: can the fetus hear the wave and feel the heat? Ultraschall Med. 2012; 33 (3): 215–217. https://doi.org/10.1055/s-0032-1312759Test; Aiken C.E., Lees C.C. Long-term effects of in utero Doppler ultrasound scanning-a developmental programming perspective. Med. Hypotheses. 2012; 78 (4): 539–541. https://doi.org/10.1016/j.mehy.2012.01.030Test; Tirada N., Dreizin D., Khati N.J. et al. Imaging pregnant and lactating patients. RadioGraphics. 2015; 35 (6): 1751–1765. https://doi.org/10.1148/rg.2015150031Test; Wei K., Mulvagh S.L., Carson L. et al. The safety of definity and optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J. Am. Soc. Echocardiogr. 2008; 21 (11): 1202–1206. https://doi.org/10.1016/j.echo.2008.07.019Test; Piscaglia F., Bolondi L., Italian Society for Ultrasound in Medicine and Biology (SIUMB) study group on ultrasound contrast agents. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med. Biol. 2006; 32 (9): 1369–1375. https://doi.org/10.1016/j.ultrasmedbio.2006.05.031Test; Sidhu P.S., Cantisani V., Dietrich C.F. et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (Long Version). Ultraschall Med. 2018; 39 (2): e2–e44. https://doi.org/10.1055/a-0586-1107Test; Perelli F., Turrini I., Giorgi M.G. et al. Contrast agents during pregnancy: pros and cons when really needed. Int. J. Environ. Res. Public Health. 2022; 19 (24): 16699. https://doi.org/10.3390/ijerph192416699Test; Kanal E., Barkovich A.J., Bell C. et al.; ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007; Am. J. Roentgenol. 2007. 188 (6): 1447–1474. https://doi.org/10.2214/AJR.06.1616Test; Hartwig V., Giovannetti G., Vanello N. et al. Biological effects and safety in magnetic resonance imaging: a review. Int. J. Environ. Res. Public Health. 2009; 6 (6): 1778–1798. https://doi.org/10.3390/ijerph6061778Test; Chartier A.L., Bouvier M.J., McPherson D.R. et al. The safety of maternal and fetal MRI at 3T. Am. J. Roentgenol. 2019; 213 (5): 1170–1173. https://doi.org/10.2214/AJR.19.21400Test; Ray J.G., Vermeulen M.J., Bharatha A. et al. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA. 2016; 316 (9): 952–961. https://doi.org/10.1001/jama.2016.12126Test; Gomes M., Matias A., Macedo F. Risks to the fetus from diagnostic imaging during pregnancy: review and proposal of a clinical protocol. Pediatr. Radiol. 2015; 45 (13): 1916–1929. https://doi.org/10.1007/s00247-015-3403-zTest; Mervak B.M., Altun E., McGinty K.A. et al. MRI in pregnancy: Indications and practical considerations. J. Magn. Reson. Imaging. 2019; 49 (3): 621–631. https://doi.org/10.1002/jmri.26317Test; Синицын В.Е. Безопасность магнитно-резонансной томографии – современное состояние вопроса. Диагностическая и интервенционная радиология. 2010. 4 (3): 61–66. https://doi.org/10.25512/DIR.2010.04.3.10Test; Behzadi A.H., Zhao Y., Farooq Z., Prince M.R. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology. 2018; 286 (2): 471–482. https://doi.org/10.1148/radiol.2017162740Test; Fraum T.J., Ludwig D.R., Bashir M.R., Fowler K.J. Gadolinium-based contrast agents: a comprehensive risk assessment. J. Magn. Reson. Imaging. 2017; 46 (2): 338–353. https://doi.org/10.1002/jmri.25625Test; Cheong B.Y.C., Wilson J.M., Preventza O.A., Muthupillai R. Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use. Tex. Heart Inst. J. 2022; 49 (3): e217680. https://doi.org/10.14503/THIJ-21-7680Test; Potts J., Lisonkova S., Murphy D.T., Lim K. Gadolinium magnetic resonance imaging during pregnancy associated with adverse neonatal and post-neonatal outcomes. J. Pediatr. 2017; 180: 291–294. https://doi.org/10.1016/j.jpeds.2016.10.061Test; Costello J.R., Kalb B., Martin D.R. Incidence and risk factors for gadolinium-based contrast agent immediate reactions. Top. Magn. Reson. Imaging. 2016; 25 (6): 257–263. https://doi.org/10.1097/RMR.0000000000000109Test; Cowper S.E., Boyer P.J. Nephrogenic systemic fibrosis: An update. Curr. Rheumatol. Rep. 2006; 8 (2): 151–157. https://doi.org/10.1007/s11926-006-0056-9Test; Kanal E., Tweedle M.F. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology. 2015; 275 (3): 630–634. https://doi.org/10.1148/radiol.2015150805Test; Kodzwa R. ACR manual on contrast media: 2018 updates. Radiol. Technol. 2019; 91 (1): 97–100.; De Santis M., Straface G., Cavaliere A.F. et al. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet. Gynecol. Scand. 2007; 86 (1): 99–101. https://doi.org/10.1080/00016340600804639Test; Thomsen H.S. ESUR guidelines on contrast agents version 10.0. Contrast Media Safety Committee, 2018; 44 p.; Gatta G., Di Grezia G., Cuccurullo V. et al. MRI in pregnancy and precision medicine: a review from literature. J. Pers. Med. 2021; 12 (1): 1–16. https://doi.org/10.3390/jpm12010009Test; Ghaghada K.B., Starosolski Z.A., Bhayana S. et al. Pre-clinical evaluation of a nanoparticle-based blood-pool contrast agent for MR imaging of the placenta. Placenta. 2017; 57: 60–70. https://doi.org/10.1016/j.placenta.2017.06.008Test; Семенова Е.С., Мащенко И.А., Труфанов Г.Е. Магнитно-резонансная томография при беременности: актуальные вопросы безопасности. Российский Электронный журнал лучевой диагностики. 2020; 10 (1): 216–230. https://doi.org/10.21569/2222-7415-2020-10-1-216-230Test; Ratnapalan S., Bentur Y., Koren G. Doctor, will that x-ray harm my unborn child? CMAJ. 2008; 179 (12): 1293–1296. https://doi.org/10.1503/cmaj.080247Test; Brent R.L. Protection of the gametes embryo/fetus from prenatal radiation exposure. Health Physics. 2015; 108 (2): 242–274. https://doi.org/10.1097/HP.0000000000000235Test; Санитарные правила и нормативы. Нормы радиационной безопасности (НРБ–99/2009): cанитарно-эпидемиологичeские правила и нормативы. Москва – Федеральный центр гигиены и эпидемиологии Роспотребнадзора. 2009. 100 c.; ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation [Electronic resource]. URL: https://www.acr.org/Clinical-Resources/Radiology-Safety/Radiation-SafetyTest (accessed: 05.03.2023).; Публикация 103 Международной комиссии по радиационной защите (МКРЗ): Пер. с англ. / Под. общей ред. М.Ф. Киселёва, Н.К. Шандалы. М.: Изд-во ООО ПКФ “Алана”, 2009. 344 с.; Крылов А.С., Наркевич Б.Я., Рыжков А.Д. Определение дозы-облучения плода у беременных женщин с раком молочной железы при сцинтиграфии сторожевых лимфатических узлов. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021; 4 (4); 78–87. https://doi.org/10.37174/2587-7593-2021-4-4-78-87Test; Raman S.P., Johnson P.T., Deshmukh S. et al. CT dose reduction applications: available tools on the latest generation of CT scanners. J. Am. Coll. Radiol. 2013. 10 (1): 37–41. https://doi.org/10.1016/j.jacr.2012.06.025Test; Colletti P.M., Micheli O.A., Lee K.H. To shield or not to shield: application of bismuth breast shields. Am. J. Roentgenol. 2013; 200 (3): 503–507. https://doi.org/10.2214/AJR.12.9997Test; Кондрашов И.А., Мандал В. Неионные низкоосмолярные мономерные йодированные рентгеноконтрастные средства: некоторые аспекты использования при проведении компьютерной томографии у детей. Медицинская визуализация. 2017; 6: 118–129. https://doi.org/10.24835/1607-0763-2017-6-118-129Test; Webb J.A., Thomsen H.S., Morcos S.K; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur. Radiol. 2005; 15 (6): 1234–1240. https://doi.org/10.1007/s00330-004-2583-yTest; Rajaram S., Exley C.E., Fairlie F., Matthews S. Effect of antenatal iodinated contrast agent on neonatal thyroid function. Br. J. Radiol. 2012; 85 (1015): e238–e242. https://doi.org/10.1259/bjr/29806327Test; Kochi M.H., Kaloudis E.V., Ahmed W., Moore W.H. Effect of in utero exposure of iodinated intravenous contrast on neonatal thyroid function. J. Comput. Assist. Tomogr. 2012; 36 (2): 165–169. https://doi.org/10.1097/rct.0b013e31824cc048Test; Зиновьев А.Н., Мотовилова Т.М., Качалина Т.С. Место количественной оценки проходимости маточных труб в определении прогноза лечения трубно-перитонеального бесплодия. РМЖ. Мать и дитя. 2013; 21 (14): 760.; American College of Radiology. Manual on contrast media, version 10.2; American College of Radiology: Reston, VA, USA, 2023. 148 p.; Wang P.I., Chong S.T., Kielar A.Z. et al. Imaging of pregnant and lactating patients: part 2, evidence-based review and recommendations. Am. J. Roentgenol. 2012; 198 (4): 785–792. https://doi.org/10.2214/AJR.11.8223Test; Despierres M., Boudy A.S., Selleret L. et al. Feasibility, safety and impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé à La Grossesse) network. Acta Oncol. 2022; 61 (3): 302–308. https://doi.org/10.1080/0284186X.2021.2004323Test; Zanotti-Fregonara P., Champion C., Trébossen R. et al. Estimation of the beta+ dose to the embryo resulting from 18F-FDG administration during early pregnancy. J. Nucl. Med. 2008; 49 (4): 679–682. https://doi.org/10.2967/jnumed.107.048900Test; Benveniste H., Fowler J.S., Rooney W.D. et al. Maternal-fetal in vivo imaging: a combined PET and MRI study. J. Nucl. Med. 2003; 44 (9): 1522–1530.; Zanotti-Fregonara P., Ishiguro T., Yoshihara K. et al. 18F-FDG fetal dosimetry calculated with PET/MRI. J. Nucl. Med. 2022; 63 (10): 1592–1597. https://doi.org/10.2967/jnumed.121.263561Test; Gropper A.B., Calvillo K.Z., Dominici L. et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann. Surg. Oncol. 2014; 21 (8): 2506–2511. https://doi.org/10.1245/s10434-014-3718-2Test; Han S.N., Amant F., Cardonick E.H. et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Res. Treat. 2018; 168 (2): 551–557. https://doi.org/10.1007/s10549-017-4611-zTest; Han S.N., Amant F., Michielsen K. et al. Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. Eur. Radiol. 2018; 28 (5): 1862–1874. https://doi.org/10.1007/s00330-017-5126-zTest; https://medvis.vidar.ru/jour/article/view/1408Test

الإتاحة: https://doi.org/10.24835/1607-0763-1408Test
https://doi.org/10.22328/2079-5343-2017-4-6-15Test
https://doi.org/10.1093/annonc/mdz228Test
https://doi.org/10.3390/jcm11133820Test
https://doi.org/10.1016/S1470-2045Test(18)30059-7
https://doi.org/10.1016/j.mehy.2012.01.030Test
https://doi.org/10.1148/rg.2015150031Test
https://doi.org/10.1016/j.echo.2008.07.019Test
https://doi.org/10.1016/j.ultrasmedbio.2006.05.031Test
https://doi.org/10.1055/a-0586-1107Test

View record in BASE

3

دورية أكاديمية

Continuous Approach in the Theory of Interaction of Charged Particles with Solids

المؤلفون: N. T. Kvasov, V. I. Yarmolik, E. R. Pavlovskaya

المصدر: Doklady Belorusskogo gosudarstvennogo universiteta informatiki i radioèlektroniki, Vol 20, Iss 6, Pp 5-13 (2022)

مصطلحات موضوعية: range of ions in matter, radiation defect, radiation modification of solids, threshold displacement energy, Electronics, TK7800-8360

وصف الملف: electronic resource

العلاقة: https://doklady.bsuir.by/jour/article/view/3437Test; https://doaj.org/toc/1729-7648Test

الوصول الحر: https://doaj.org/article/706d1846a91e45188a39e6f3fa40109cTest

View record in DOAJ

4

دورية أكاديمية

Taxonomic structure of bacterial communities in sourdoughs of spontaneous fermentation

المؤلفون: V. K. Khlestkin, M. N. Lockachuk, O. A. Savkina, L. I. Kuznetsova, E. N. Pavlovskaya, O. I. Parakhina

المصدر: Вавиловский журнал генетики и селекции, Vol 26, Iss 4, Pp 385-393 (2022)

مصطلحات موضوعية: rye sourdough, microbiome, microbial community, lactobacillus, high-throughput sequencing, fermentation, bakery products, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: https://vavilov.elpub.ru/jour/article/view/3389Test; https://doaj.org/toc/2500-3259Test

الوصول الحر: https://doaj.org/article/c606e21d11e3458e95f375a696f7190dTest

View record in DOAJ

النص الكامل

5

دورية أكاديمية

Features of Microbiota in Newborns in Critical Condition at Admission to the Intensive Care Unit of a Specialized Hospital

المؤلفون: Yu. S. Aleksandrovich, D. O. Ivanov, E. Yu. Pavlovskaya, K. V. Pshenisnov, A. M. Savicheva, K. V. Shalepo, T. I. Akimenko, D. A. Zemlyanoy

المصدر: Вестник анестезиологии и реаниматологии, Vol 19, Iss 2, Pp 56-63 (2022)

مصطلحات موضوعية: новорожденные, инфекции неонатального периода, критическое состояние, антибактериальная терапия, отделение интенсивной терапии новорожденных, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

وصف الملف: electronic resource

العلاقة: https://www.vair-journal.com/jour/article/view/649Test; https://doaj.org/toc/2078-5658Test; https://doaj.org/toc/2541-8653Test

الوصول الحر: https://doaj.org/article/5965d33231924826b7b57d092bd118e6Test

View record in DOAJ

6

دورية أكاديمية

Imaging of cervical cancer. Consensus of experts ; Лучевая диагностика рака шейки матки. Консенсус экспертов

المؤلفون: N. A. Rubtsova, T. P. Berezovskaia, V. G. Bychenko, E. A. Pavlovskaya, A. E. Solopova, T. A. Agababyan, M. M. Khodzhibekova, D. V. Ryzhkova, M. A. Chekalova, I. E. Meshkova, V. E. Gazhonova, A. I. Gus, S. S. Bagnenko, B. M. Medvedeva, L. A. Ashrafyan, E. G. Novikova, I. V. Berlev, L. V. Demidova, L. I. Krikunova, L. A. Kolomiets, Н. А. Рубцова, Т. П. Березовская, В. Г. Быченко, Е. А. Павловская, А. Е. Солопова, Т. А. Агабабян, М. М. Ходжибекова, Д. В. Рыжкова, М. А. Чекалова, И. Е. Мешкова, В. Е. Гажонова, А. И. Гус, С. С. Багненко, Б. М. Медведева, Л. А. Ашрафян, Е. Г. Новикова, И. В. Берлев, Л. В. Демидова, Л. И. Крикунова, Л. А. Коломиец

المصدر: Medical Visualization; Том 28, № 1 (2024); 141-156 ; Медицинская визуализация; Том 28, № 1 (2024); 141-156 ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: 18 F-фтордезоксиглюкоза, imaging, MRI, US, FGD PET/CT, МРТ, УЗИ, ПЭТ/КТ

وصف الملف: application/pdf

العلاقة: https://medvis.vidar.ru/jour/article/view/1341/854Test; FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009; 105 (2): 103–104. http://doi.org/10.1016/j.ijgo.2009.02.012Test; FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 2019; 145 (1): 129–135. http://doi.org/10.1002/ijgo.12749Test; Bhatla N., Aoki D., Sharma D.N., Sankaranarayanan R. Cancer of the cervix uteri. Int. J. Gynaecol. Obstet. 2018; 143 (Suppl. 2): 22–36. http://doi.org/10.1002/ijgo.12611Test; Berek J.S., Matsuo K., Grubbs B.H. et al. Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. J. Gynecol. Oncol. 2019; 30 (2): e40. http://doi.org/10.3802/jgo.2019.30.e40Test; Bhatla N., Aoki D., Sharma D.N., Sankaranarayanan R. Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri”. Int. J. Gynecol. Obstet. 2019; 145: 129–135. http://doi.org/10.1002/ijgo.12969Test; Lee S.I., Atri M. 2018 FIGO staging system for uterine cervical cancer: enter cross-sectional imaging. Radiology. 2019; 292 (1): 15–24. http://doi.org/10.1148/radiol.2019190088Test; Olawaiye A.B., Baker T.P., Washington M.K., Mutch D.G. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J. Clin. 2021; 71 (4): 287–298. http://doi.org/10.3322/caac.21663Test; FIGO CANCER REPORT 2021 Cancer of the cervix uteri: 2021 update International Journal of Obstetrics and Gynaecology. 155 (S1). Special Issue: FIGO Cancer Report 2021 October: 28–44. https://doi.org/10.1002/ijgo.13967Test; Клинические рекомендации, одобренные научным советом МЗ РФ, Рак шейки матки, 2020 г. 48 с. https://oncology.ru/specialist/treatment/references/actual/537.pdf?ysclid=lp6m9w7k57670993368Test; Tian Y., Luo H. Diagnostic accuracy of transvaginal ultrasound examination for local staging of cervical cancer: a systematic review and meta-analysis. Med. Ultrason. 2022; 24 (3): 348–355. http://doi.org/10.11152/mu-3246Test; Cibula D., Pötter R., Planchamp F. et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int. J. Gynecol. Cancer. 2018; 28 (4): 641–655. http://doi.org/10.1097/IGC.0000000000001216Test; Marth C., Landoni F., Mahner S. et al.; ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017; 28 (Suppl_4): iv72–iv83. http://doi.org/10.1093/annonc/mdx220Test; Chino J., Annunziata C.M., Beriwal S. et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol. 2020; 10 (4): 220–234. http://doi.org/10.1016/j.prro.2020.04.002Test; Hricak H., Gatsonis C., Chi D.S. et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J. Clin. Oncol. 2005; 23 (36): 9329–9337. http://doi.org/10.1200/JCO.2005.02.0354Test; Xiao M., Yan B., Li Y. et al. Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis. Eur. Radiol. 2020; 30 (3): 1405–1418. http://doi.org/10.1007/s00330-019-06461-9Test; Thomeer M.G., Gerestein C., Spronk S. et al. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma:systematic review and meta-analysis. Eur. Radiol. 2013; 23: 2005–2018. http://doi.org/10.1007/s00330-013-2783-4Test; Manganaro L., Lakhman Y., Bharwani N. et al. Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018. Eur. Radiol. 2021; 31 (10): 7802–7816. http://doi.org/10.1007/s00330-020-07632-9Test. Erratum in: Eur. Radiol. 2021 Jun 17. PMID: 33852049; Bourgioti C., Chatoupis K., Moulopoulos L.A. Current imaging strategies for the evaluation of uterine cervical cancer. Wld J. Radiol. 2016; 8 (4): 342–354. http://doi.org/10.4329/wjr.v8.i4.342Test; Nogami Y., Iida M., Banno K. et al. Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects. Anticancer Res. 2014; 34 (2): 585–592. PMID: 24510987; Mirpour S., Mhlanga J., Logeswaran P. et al. The role of PET/CT in the management of cervical cancer. Am. J. Roentgenol. 2013; 201 (2): W192–205. http://doi.org/10.2214/AJR.12.9830Test; Choi H.J., Ju W., Myung S.K., Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010; 101 (6): 1471–1479. http://doi.org/10.1111/j.1349-7006.2010.01532.xTest; Liu B., Gao S., Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/ CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a metaanalysis based on 67 studies. Gynecol. Obstet Invest. 2017; 82 (3): 209–222. http://doi.org/10.1159/000456006Test; Ruan J., Zhang Y., Ren H. Meta-analysis of PET/CT Detect Lymph Nodes Metastases of Cervical Cancer. Open Med. (Wars.) 2018; 13: 436–442. http://doi.org/10.1515/med-2018-0065Test; Young P., Daniel B., Sommer G. et al. Intravaginal gel for staging of female pelvic cancers–preliminary report of safety, distention, and gel-mucosal contrast during magnetic resonance examination. J. Comput. Assist. Tomogr. 2012; 36 (2): 253–256. http://doi.org/10.1097/RCT.0b013e3182483c05Test; Van Hoe L., Vanbeckevoort D., Oyen R. et al. Cervical carcinoma: optimized local staging with intravaginal contrast-enhanced MR imaging–preliminary results. Radiology. 1999; 213 (2): 608–611. http://doi.org/10.1148/radiology.213.2.r99oc23608Test; Akata D., Kerimoglu U., Hazirolan T. et al. Efficacy of transvaginal contrast-enhanced MRI in the early staging of cervical carcinoma. Eur. Radiol. 2005; 15 (8): 1727–1733. https://doi.org/10.1007/s00330-005-2645-9Test; Li X., Wang L., Li Y., Song P. The value of diffusionweighted imaging in combination with conventional magnetic resonance imaging for improving tumor detection for early cervical carcinoma treated with fertility-sparing surgery. Int. J. Gynecol. Cancer. 2017; 27 (8):1761–1768. http://doi.org/10.1097/IGC.0000000000001113Test; Woo S., Moon M.H., Cho J.Y. et al. Diagnostic performance of MRI for assessing parametrial invasion in cervical cancer: a head-to-head comparison between oblique and true axial T2-weighted images. Korean J. Radiol. 2019; 20 (3): 378–384. http://doi.org/10.3348/kjr.2018.0248Test; Hori M., Kim T., Onishi H. et al Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T-initial experience. Radiology. 2011; 258 (1): 154–163. http://doi.org/10.1148/radiol.10100866Test; Hwang J., Hong S.S., Kim H.J. et al. Reduced field-of-view diffusion-weighted MRI in patients with cervical cancer. Br. J. Radiol. 2018; 91 (1087): 20170864. http://doi.org/10.1259/bjr.20170864Test; Huang J.-W., Song J.-C., Chen T. et al. Making the invisible visible: improving detectability of MRI-invisible residual cervical cancer after conisation by DCE-MRI. Clin. Radiol. 2019; 74 (2): 166.e15–166.e21. http://doi.org/10.1016/j.crad.2018.10.013Test; Bermudez A., Bhatla N., Leung E. FIGO cancer report 2015. Cancer of the cervix uteri. Int. J. Gynecol. Obstet. 2015; 131: S88–95. http://doi.org/10.1016/j.ijgo.2015.06.004Test; Bentivegna E., Gouy S., Maulard A. et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016; 17 (6): e240–e253. http://doi.org/10.1016/S1470-2045Test(16)30032-8; Zhang Q., Li W., Kanis M.J. et al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8 (28): 46580–46592. http://doi.org/10.18632/oncotarget.16233Test; Bentivegna E., Maulard A., Pautier P. et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the Literature. Fertil Steril. 2016; 106 (5): 1195–1211.e5. https://doi.org/10.1016/j.fertnstert.2016.06.032Test; Koh W.J., Abu-Rustum N.R., Bean S. et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2019; 17 (1): 64–84. http://doi.org/10.6004/jnccn.2019.0001Test; Engin G. Cervical cancer: MR imaging findings before, during, and after radiation therapy. Eur. Radiol. 2006; 16 (2): 313–324. http://doi.org/10.1007/s00330-005-2804-zTest; Hricak H., Yu K.K. Radiology in invasive cervical cancer. Am. J. Roentgenol. 1996; 167: 1101–1108. http://doi.org/10.2214/ajr.167.5.8911159Test; Lakhman Y., Akin O., Park K.J. et al. Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy. Radiology. 2013; 269 (1): 149–158. https://doi.org/10.1148/radiol.13121746Test; Noël P., Dubé M., Plante M., St-Laurent G. Early cervical carcinoma and fertility-sparing treatment options: MR imaging as a tool in patient selection and a follow-upmodality. Radiographics. 2014; 34 (4): 1099–1119. https://doi.org/10.1148/rg.344130009Test; Downey K., Attygalle A.D., Morgan V.A. et al. Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. Eur. Radiol. 2016; 26 (4): 941–950. http://doi.org/10.1007/s00330-015-3899-5Test; DeSouza N.M., Rockall A., Freeman S. Functional MR imaging in gynecologic cancer. Magn. Reson. Imaging Clin. N. Am. 2016; 24 (1): 205–222. http://doi.org/10.1016/j.mric.2015.08.008Test; Woo S., Suh C.H., Kim S.Y. et al. Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: an updated systematic review and meta-analysis of the literature between 2012 and 2016. Eur. Radiol. 2018; 28 (2): 530–541. http://doi.org/10.1007/s00330-017-4958-xTest; Park J.J., Kim C.K., Park S.Y., Park B.K. Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T. Radiology. 2015; 274 (3): 734–741. http://doi.org/10.1148/radiol.14140920Test; Sala E., Rockall A.G., Freeman S.J. et al. The Added Role of MR Imaging in Treatment Stratification of Patients with Gynecologic Malignancies: What the Radiologist Needs to Know. Radiology. 2013; 266: 717–740. http://doi.org/10.1148/radiol.12120315Test; Raithatha A., Papadopoulou I., Stewart V. et al. Cervical cancer staging: a resident’s primer: women’s imaging. Radiographics. 2016; 36 (3): 933–934. http://doi.org/10.1148/rg.2016150173Test; Eisenhauer E.A., Therasse P., Bogaerts J. et. al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009; 45 (2): 228–247. http://doi.org/10.1016/j.ejca.2008.10.026Test; Zhang A., Song J., Ma Z., Chen T. Application of apparent diffusion coefficient values derived from diffusion-weighted imaging for assessing different sized metastatic lymph nodes in cervical cancers. Acta Radiol. 2020; 61 (6): 848–855. https://doi.org/10.1177/0284185119879686Test; Qi Y.F., He Y.L., Lin C.Y. et al. Diffusion-weighted imaging of cervical cancer: Feasibility of ultra-high b-value at 3T. Eur. J. Radiol. 2020; 124: 108779. http://doi.org/10.1016/j.ejrad.2019.108779Test; Elsholtz F.H.J., Asbach P., Haas M. et al. Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur. Radiol. 2021; 31 (8): 6116–6124. https://doi.org/10.1007/s00330-020-07572-4Test; Wong T.Z., Jones E.L., Coleman R.E. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol. Imaging Biol. 2004; 6 (1): 55–62. http://doi.org/10.1016/j.mibio.2003.12.004Test; Hameeduddin A., Sahdev A. Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging. 2015; 15 (1): 3. http://doi.org/10.1186/s40644-015-0037-1Test; Young H., Baum R., Cremerius U. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999; 35 (13): 1773–1782. http://doi.org/10.1016/s0959-8049Test(99)00229-4; Wang X., Koch S. Positron emission tomography/ computed tomography potential pitfalls and artifacts. Curr. Probl. Diagn. Radiol. 2009; 38 (4): 156–169. http://doi.org/10.1067/j.cpradiol.2008.01.001Test; Amit A., Person O., Keidar Z. FDG PET/CT in monitoring response to treatment in gynecological malignancies. Curr. Opin. Obstet. Gynecol. 2013; 25 (1): 17–22. http://doi.org/10.1097/GCO.0b013e32835a7e96Test; American College of Radiology ACR Appropriateness Criteria: Pretreatment Planning of Invasive Cancer of the Cervix. https://acsearch.acr.org/docs/69461/NarrativeTest/; Moore K.N., Herzog T.J., Lewin S. et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol. Oncol. 2007; 105 (2): 299–303. http://doi.org/10.1016/j.ygyno.2006.12.031Test; Lorusso D., Petrelli F., Coinu A. et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol. Oncol. 2014; 133 (1): 117–123. http://doi.org/10.1016/j.ygyno.2014.01.042Test; Bodurka-Bevers D., Morris M., Eifel P.J. et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol. Oncol. 2000; 78 (2): 187–193. http://doi.org/10.1006/gyno.2000.5860Test.; Scottish Intercollegiate Guidelines Network. Management of cervical cancer/ (SIGN guideline no 99) 2008; National Comprehensive Cancer Network (NCCN) guidelines for cervical cancer/ 2022; https://medvis.vidar.ru/jour/article/view/1341Test